ProQR Therapeutics (PRQR) EBT Margin (2021 - 2025)
Historic EBT Margin for ProQR Therapeutics (PRQR) over the last 5 years, with Q3 2025 value amounting to 391.53%.
- ProQR Therapeutics' EBT Margin fell 1647300.0% to 391.53% in Q3 2025 from the same period last year, while for Sep 2025 it was 288.67%, marking a year-over-year decrease of 1392000.0%. This contributed to the annual value of 147.9% for FY2024, which is 2790800.0% up from last year.
- According to the latest figures from Q3 2025, ProQR Therapeutics' EBT Margin is 391.53%, which was down 1647300.0% from 320.91% recorded in Q2 2025.
- Over the past 5 years, ProQR Therapeutics' EBT Margin peaked at 57.1% during Q2 2024, and registered a low of 8583.69% during Q1 2021.
- Over the past 5 years, ProQR Therapeutics' median EBT Margin value was 731.2% (recorded in 2023), while the average stood at 1834.7%.
- Within the past 5 years, the most significant YoY rise in ProQR Therapeutics' EBT Margin was 70753700bps (2022), while the steepest drop was -7658800bps (2022).
- Quarter analysis of 5 years shows ProQR Therapeutics' EBT Margin stood at 7250.21% in 2021, then surged by 76bps to 1730.56% in 2022, then skyrocketed by 89bps to 190.86% in 2023, then decreased by -23bps to 234.06% in 2024, then crashed by -67bps to 391.53% in 2025.
- Its EBT Margin was 391.53% in Q3 2025, compared to 320.91% in Q2 2025 and 239.34% in Q1 2025.